Efficacy and Clinical Outcomes of Remdesivir Plus Intravenous Cefepime Compared to Remdesivir Plus Intravenous Levofloxacin in Type 2 Diabetes Mellitus Iraqi Patients with COVID -19
Abstract
Objectives: Diabetes mellitus is one of critical causes of mortality annually. As the corona virus (covid 19) spread epidemicallyand has many proposed treatment methods. Remdesivir is one of the approved drugs that has antiviral activity inhibitingcovid 19 in vitro and in vivo. Moreover, Remdesivir should be accompanied by other complementary medications to reducehospitalization time. Among these drugs was levofloxacin and cefepime. This study shows the clinical outcome of cefepime andcompare it with levofloxacin when combined with remdesivir as adjuvant drug in diabetic patients diagnosed with COVID-19.Materials and Methods: A retrospective multicenter study on 75 diabetic patients confirmed with COVID-19 diagnosis. Thepatients divided in two groups first group of 40 patients received remdesivir with intravenous levofloxacin, the second groupinclude 35 patients received remdesivir plus intravenous cefepime.Results: Preliminary and rapid remdesivir treatment has revealed a good result. Interestingly, Cefepime and levofloxacinenhance mean D-dimer level from 0.9 µg/L to (0.8 µg/L and 0.85 µg/L respectively), mean CRP level from 65 µmol/L to(45 µmol/L and 51 µmol/L respectively) and LDH mean level from 250 (U/L) to (170 U/L in cefepime) versus (200 U/L inlevofloxacin). Noteworthy, there were multiple parameters worsened by levofloxacin like ferritin level that turned from 920µg/L to 500 µg/L in Cefepime versus 1029 µg/L in levofloxacin group. About mean recovery time in days…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.